Key points are not available for this paper at this time.
We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% 95% CI 74%-83%) in the same season as vaccine receipt.
Wiegand et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: